Skip to main content

Table 3 HOMA-β and HOMA-IR in Sitagliptin group and Control group

From: Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus

  Sitagliptin group (n = 17)
Month of Study 0 6 12 24 48 72 96 120
HOMA-β 15.6 (8.81) 13.1 (8.15) 19.5 (10.5) 20.3 (7.41)* 24.6 (8.60)* 28.12 (8.91)* 31.2 (12.2)* 31.4 (10.41)*
HOMA-IR 1.15 (0.74) 1.14 (0.63) 1.14 (0.60) 1.12 (0.59) 1.15 (0.61) 1.18 (0.55) 1.14 (0.61) 1.15 (0.54)
  Control group (n = 9)
Month of Study 0 6 12 24 48 72 96 120
HOMA-β 21.6 (18.7) 22.0 (16.6) 19.5 (13.1) 22.4 (18.7) 20.9 (21.2) 21.1 (4.2) 24.2 (18.5) 23.2 (18.4)
HOMA-IR 1.14 (0.81) 1.36 (0.67) 1.27 (0.61) 1.41 (0.74) 1.29 (0.76) 1.21 (0.66) 1.22 (0.52) 1.17 (0.50)
  1. Values are shown as means ± SD in parentheses
  2. HOMA-β, homeostatic model assessment of β cell function, HOMA-IR homeostatic model assessment of insulin resistance
  3. *Intragroup comparison: p < 0.05 (paired t test)